National Poisons Information Service, NHS Lothian, Edinburgh Napier University, Edinburgh, UK.
Edinburgh Napier University, Robert Gordon University, Aberdeen, UK.
J Adv Nurs. 2024 Nov;80(11):4361-4371. doi: 10.1111/jan.16181. Epub 2024 Apr 2.
To explore healthcare professionals' perceptions and experiences of take-home naloxone initiatives in acute care settings to gain an understanding of issues facilitating or impeding dispensing.
Systematic literature review.
Cochrane, MEDLINE and CINAHL were searched from 15/03/2021 to 18/03/2021, with a follow-up search performed via PubMed on 22/03/2021. The years 2011 to 2021 were included in the search.
A systematic literature review focused on qualitative studies and quantitative survey designs. Synthesis without meta-analysis was undertaken using a thematic analysis approach.
Seven articles from the United States of America (5), Australia (1) and Canada (1) with 750 participants were included in the review. Results indicate ongoing stigma towards people who use drugs with preconceived moral concerns regarding take-home naloxone. There was confusion regarding roles and responsibilities in take-home naloxone dispensing and patient education. Similarly, there was a lack of clarity over logistical and financial issues.
Take-home naloxone is a vital harm reduction initiative. However, barriers exist that prevent the optimum implementation of these initiatives.
What is already known: Deaths due to opioid overdose are a global health concern, with take-home naloxone emerging as a key harm reduction scheme. Globally, less than 10% of people who use drugs have access to treatment initiatives, including take-home naloxone. An optimum point of distribution of take-home naloxone is post-acute hospital care.
There is role confusion regarding responsibility for the provision of take-home naloxone and patient education. This is exacerbated by inconsistent provision of training and education for healthcare professionals. Logistical or financial concerns are common and moral issues are prevalent with some healthcare professionals questioning the ethics of providing take-home naloxone. Stigma towards people who use drugs remains evident in some acute care areas which may impact the use of this intervention. Implications for practice/policy: Further primary research should examine what training and education methods are effective in improving the distribution of take-home naloxone in acute care. Education should focus on reduction of stigma towards people who use drugs to improve the distribution of take-home naloxone. Standardized care guidelines may ensure interventions are offered equally and take-home naloxone 'champions' could drive initiatives forward, with support from harm reduction specialists.
This has adhered to the PRISMA reporting guidelines for systematic reviews.
No patient or public contribution.
探索医疗保健专业人员对急性护理环境中纳洛酮家庭使用计划的看法和经验,以了解促进或阻碍配药的问题。
系统文献回顾。
Cochrane、MEDLINE 和 CINAHL 于 2021 年 3 月 15 日至 18 日进行检索,并于 2021 年 3 月 22 日通过 PubMed 进行了后续搜索。检索范围包括 2011 年至 2021 年。
系统文献综述重点关注定性研究和定量调查设计。使用主题分析方法进行无荟萃分析的综合。
综述纳入了来自美国(5 篇)、澳大利亚(1 篇)和加拿大(1 篇)的 7 篇文章,共有 750 名参与者。结果表明,人们对吸毒者仍存在持续的污名化,存在先入为主的道德担忧,对纳洛酮家庭使用存在偏见。在纳洛酮家庭配药和患者教育方面,对角色和责任存在混淆。同样,在后勤和财务问题上也缺乏明确性。
纳洛酮家庭使用是一项重要的减少伤害计划。然而,存在一些障碍,阻碍了这些计划的最佳实施。
已知的是:阿片类药物过量导致的死亡是一个全球性的健康问题,纳洛酮家庭使用作为一种关键的减少伤害方案出现。全球范围内,只有不到 10%的吸毒者能够获得治疗措施,包括纳洛酮家庭使用。纳洛酮家庭使用的最佳分发点是急性医院护理后。
在纳洛酮家庭使用和患者教育的提供方面存在角色混淆。这因医疗保健专业人员培训和教育的不一致而加剧。后勤或财务方面的问题很常见,一些医疗保健专业人员质疑提供纳洛酮家庭使用的道德问题。在一些急性护理领域,对吸毒者的污名化仍然存在,这可能会影响该干预措施的使用。
对实践/政策的影响:应进一步开展初步研究,以探讨哪些培训和教育方法可有效提高急性护理中纳洛酮家庭使用的分发。教育应侧重于减少对吸毒者的污名化,以改善纳洛酮家庭使用的分发。标准化的护理指南可确保干预措施平等提供,纳洛酮“拥护者”可以在减少伤害专家的支持下推动倡议。
本研究符合系统评价的 PRISMA 报告指南。
无患者或公众贡献。